<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027534</url>
  </required_header>
  <id_info>
    <org_study_id>2840</org_study_id>
    <secondary_id>1R21CA094523</secondary_id>
    <secondary_id>2840</secondary_id>
    <secondary_id>CDR0000069041</secondary_id>
    <nct_id>NCT00027534</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase I Study Of Active Immunotherapy With Autologous Dendritic Cells Infected With CEA-6D Expressing Fowlpox -Tricom In Patients With Advanced Or Metastatic Malignancies Expressing CEA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Morse, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's white blood cells that have been treated in the&#xD;
      laboratory may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who&#xD;
      have advanced or metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and feasibility of active immunotherapy comprising autologous&#xD;
           dendritic cells infected with recombinant fowlpox-CEA-TRICOM vaccine in patients with&#xD;
           advanced or metastatic malignancies expressing CEA.&#xD;
&#xD;
        -  Assess the CEA-specific immune response of patients treated with this regimen.&#xD;
&#xD;
        -  Assess, in a preliminary manner, the clinical response rate of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Autologous dendritic cells (ADCs) are harvested and infected with fowlpox-CEA-TRICOM vaccine.&#xD;
      Patients receive the infected ADCs intradermally and subcutaneously (SC) followed by ADCs&#xD;
      mixed with CMV pp65 peptide and ADCs mixed with tetanus toxoid SC and intradermally on day 1.&#xD;
      Treatment repeats every 3 weeks for a total of 4, 8, or 12 immunizations in the absence of&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive an escalating number of immunizations until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 6-18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12-36 weeks</time_frame>
    <description>The primary objective of this protocol is to determine the safety and feasibility of rF-CEA(6D)-TRICOM loaded DC in, subjects with metastatic, CEA expressing malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response</measure>
    <time_frame>12-36 weeks</time_frame>
    <description>The immune response to the injections of the TRICOM-CEA(6D) antigen loaded DC will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gallbladder Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Liver Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>TRICOM-CEA(6D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receiving TRICOM-CEA(6D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TRICOM-CEA(6D)</intervention_name>
    <description>dendritic cells loaded with TRICOM-CEA(6D)</description>
    <arm_group_label>TRICOM-CEA(6D)</arm_group_label>
    <other_name>recombinant fowlpox-CEA(6D)/TRICOM vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced or metastatic malignancy expressing CEA&#xD;
&#xD;
               -  Metastatic disease meeting one of the following criteria:&#xD;
&#xD;
                    -  Measurable or nonmeasurable&#xD;
&#xD;
                    -  History of metastases but no current evidence of disease, meeting one of the&#xD;
                       following criteria:&#xD;
&#xD;
                         -  Unresectable peritoneal or lymph node metastases that cannot be&#xD;
                            detected by imaging&#xD;
&#xD;
                         -  Treated or resected metastatic disease considered at high risk of&#xD;
                            recurrence (predicted 5-year disease-free survival of less than 50%)&#xD;
&#xD;
                              -  Must have completed treatment that rendered no evidence of disease&#xD;
                                 within the past year&#xD;
&#xD;
          -  CEA-expressing malignancy is defined by any of the following:&#xD;
&#xD;
               -  Immunohistochemical staining (at least 50% of the tumor has at least a moderate&#xD;
                  intensity of staining)&#xD;
&#xD;
               -  CEA level in peripheral blood greater than 2.5 Âµg/L&#xD;
&#xD;
               -  Tumor known to be universally CEA positive (e.g., colon and rectal cancer)&#xD;
&#xD;
          -  Received prior therapy with possible survival benefit or refused such therapy&#xD;
&#xD;
          -  Prior resection of brain metastases allowed provided no metastasis by CT scan or MRI&#xD;
             of the brain within 1 month of enrollment&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over Sex&#xD;
&#xD;
          -  Male or female Menopausal status&#xD;
&#xD;
          -  Not specified Performance status&#xD;
&#xD;
          -  Karnofsky 70-100% Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute lymphocyte count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL (transfusion or epoetin alfa allowed) Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT less than 1.5 times upper limit of normal&#xD;
&#xD;
          -  No active acute or chronic viral hepatitis&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
          -  No other hepatic disease that would preclude study entry&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
          -  No active acute or chronic urinary tract infection&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of autoimmune disease, including, but not limited to, the following:&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Rheumatoid arthritis&#xD;
&#xD;
               -  Ankylosing spondylitis&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
          -  No allergy to eggs or any component of study vaccine Other&#xD;
&#xD;
          -  No active acute or chronic infection&#xD;
&#xD;
          -  No concurrent serious acute or chronic illness that would preclude study entry&#xD;
&#xD;
          -  No other medical or psychological impediment that would preclude study entry&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer, controlled&#xD;
             carcinoma in situ of the cervix, or controlled superficial bladder cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy and recovered&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy and recovered&#xD;
&#xD;
          -  At least 6 weeks since prior steroids except steroids used as premedication for&#xD;
             chemotherapy or for contrast-enhanced studies&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior palliative radiotherapy (including systemic radiolabeled compounds) for unstable&#xD;
             or painful bone metastases in weight-bearing bones may be allowed&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since any other prior therapy (including experimental therapy) and&#xD;
             recovered&#xD;
&#xD;
          -  No concurrent immunosuppressives (e.g., azathioprine or cyclosporine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert K. Lyerly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Michael Morse, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>Paget disease of the breast with intraductal carcinoma</keyword>
  <keyword>Paget disease of the breast with invasive ductal carcinoma</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>diffuse adenocarcinoma of the stomach</keyword>
  <keyword>intestinal adenocarcinoma of the stomach</keyword>
  <keyword>mixed adenocarcinoma of the stomach</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the gallbladder</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>stage II malignant testicular germ cell tumor</keyword>
  <keyword>stage III malignant testicular germ cell tumor</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>cholangiocarcinoma of the gallbladder</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

